Ensartinib
First- and later-line treatment of ALK-positive non-small cell lung cancer
- CAS No.
- 1370651-20-9
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Lung Cancer
- Target / Mechanism
- ALK
- Labeled Purity
- 98%+
- Registration Readiness
- —
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A China-originated ALK inhibitor with globally competitive efficacy and safety, a mature asset for domestic innovative-drug export and licensing.
Oncology / Lung Cancer · Marketed; available for immediate sourcing
—-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Ensartinib is an oral tyrosine kinase inhibitor primarily used for the treatment of ALK positive non-small cell lung cancer (NSCLC).
Supply source: Unibest · Ensartinib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.